Based on the DarioHealth Corp stock forecast from 2 analysts, the average analyst target price for DarioHealth Corp is USD 1.67 over the next 12 months. DarioHealth Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of DarioHealth Corp is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, DarioHealth Corp’s stock price was USD 0.73. DarioHealth Corp’s stock price has changed by +29.57% over the past week, +11.91% over the past month and -41.01% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for DarioHealth Corp
No recent average analyst rating found for DarioHealth Corp
Company Overview DarioHealth Corp
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York. Read Less
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coa...Read More
Frequently Asked Questions About DarioHealth Corp (DRIO) Stock
Based on ratings from 2 analysts DarioHealth Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DRIO's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DRIO is USD 1.67 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 1.
Unfortunately we do not have enough data on DRIO's stock to indicate if its overvalued.
The last closing price of DRIO's stock was USD 0.73.
The most recent market capitalization for DRIO is USD 0.03B.
Based on targets from 2 analysts, the average taret price for DRIO is projected at USD 1.67 over the next 12 months.
This means that DRIO's stock price may go up by +129.69% over the next 12 months.
We can't find any ETFs which contains DarioHealth Corp's stock.
As per our most recent records DarioHealth Corp has 196 Employees.
DarioHealth Corp's registered address is 322 W 57th St, New York, NY, United States, 10019.
You can get more information about it from DarioHealth Corp's website at https://www.dariohealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About DarioHealth Corp (DRIO) Stock
Based on ratings from 2 analysts DarioHealth Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DRIO's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DRIO is USD 1.67 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 1.
Unfortunately we do not have enough data on DRIO's stock to indicate if its overvalued.
The last closing price of DRIO's stock was USD 0.73.
The most recent market capitalization for DRIO is USD 0.03B.
Based on targets from 2 analysts, the average taret price for DRIO is projected at USD 1.67 over the next 12 months.
This means that DRIO's stock price may go up by +129.69% over the next 12 months.
We can't find any ETFs which contains DarioHealth Corp's stock.
As per our most recent records DarioHealth Corp has 196 Employees.
DarioHealth Corp's registered address is 322 W 57th St, New York, NY, United States, 10019.
You can get more information about it from DarioHealth Corp's website at https://www.dariohealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DRIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
